Signadori Bio

Signadori BioSignadori Bio
Signadori Bio

Signadori Bio

Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.

DR 6Speed 632025InactiveParis, France
Rate

About

Signadori Bio SAS is a preclinical-stage biopharmaceutical company focused on developing an innovative immunotherapy platform. Their approach utilizes in vivo engineered monocytes, designed to be an off-the-shelf solution for treating solid tumors. The company aims to advance novel therapeutic strategies in oncology.
Frequently asked

What does Signadori Bio do?

Signadori Bio SAS is a preclinical-stage biopharmaceutical company focused on developing an innovative immunotherapy platform. Their approach utilizes in vivo engineered monocytes, designed to be an off-the-shelf solution for treating solid tumors. The company aims to advance novel therapeutic strategies in oncology.

What is Signadori Bio's revenue?

StartupHub estimates Signadori Bio's annual revenue at $1.5M (range $308K to $4.4M, 35% confidence), based on comparable companies in the sector.

What is Signadori Bio's valuation?

StartupHub estimates Signadori Bio's effective valuation at $47.6M (range $30.5M to $73.2M, 24% confidence), based on comparable companies in the sector.

How much funding has Signadori Bio raised?

Signadori Bio has raised a total of $12M in funding. The most recent round on record is Seed Extension.

Where is Signadori Bio headquartered?

Signadori Bio is headquartered in Paris, France.

When was Signadori Bio founded?

Signadori Bio was founded in 2025.

What industry does Signadori Bio operate in?

Signadori Bio operates in Biotechnology, Pharmaceuticals, Oncology, Immunotherapy, Biopharmaceuticals, Drug Discovery.

What is Signadori Bio's current status?

Signadori Bio's current operating status is: Inactive.

Comments

No comments yet. Be the first to share your take.